Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685703 | 0.85 | IDO1 (0.41) | NAAAIDO1AGXTTRPV6CA1 | |
| SCHEMBL16686216 | 0.79 | IDO1 (0.43) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL3049685 | 0.79 | NAAA (0.58) | NAAAIDO1AGXTCTSLCTSB | |
| SCHEMBL16448677 | 0.77 | IDO1 (0.41) | IDO1AGXTTRPV6CA1CA2 | |
| Methyl Alcohol SCHEMBL8601404 | 0.77 | CA1 (0.42) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL16448678 | 0.77 | IDO1 (0.41) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL15536619 | 0.76 | IDO1 (0.47) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL16685927 | 0.74 | HTT (0.45) | CA1CA2 | |
| SCHEMBL21752422 | 0.74 | SIGMAR1 (0.49) | CTSLCTSBCTSKTRPV6 | |
| SCHEMBL8233618 | 0.73 | CTSL (0.39) | NAAAIDO1AGXTCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| WO-2007060484-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | NAAA 2004/4885IDO1 243/4885AGXT 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.